CA2652061A1 - Pyrimidine low molecular weight ligands for modulating hormone receptors - Google Patents

Pyrimidine low molecular weight ligands for modulating hormone receptors Download PDF

Info

Publication number
CA2652061A1
CA2652061A1 CA002652061A CA2652061A CA2652061A1 CA 2652061 A1 CA2652061 A1 CA 2652061A1 CA 002652061 A CA002652061 A CA 002652061A CA 2652061 A CA2652061 A CA 2652061A CA 2652061 A1 CA2652061 A1 CA 2652061A1
Authority
CA
Canada
Prior art keywords
aralkyl
compound
lower alkyl
cycloalkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652061A
Other languages
English (en)
French (fr)
Inventor
Marvin C. Gershengorn
Susanne Neumann
Craig Thomas
Holger Jaeschke
Susanna Moore
Gerd Krause
Bruce Raaka
Ralf Paschke
Gunnar Kleinau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungsverbund Berlin FVB eV
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2652061A1 publication Critical patent/CA2652061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002652061A 2006-05-17 2007-05-17 Pyrimidine low molecular weight ligands for modulating hormone receptors Abandoned CA2652061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80137006P 2006-05-17 2006-05-17
US60/801,370 2006-05-17
PCT/US2007/011951 WO2007136776A2 (en) 2006-05-17 2007-05-17 Pyrimidine low molecular weight ligands for modulating hormone receptors

Publications (1)

Publication Number Publication Date
CA2652061A1 true CA2652061A1 (en) 2007-11-29

Family

ID=38566208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652061A Abandoned CA2652061A1 (en) 2006-05-17 2007-05-17 Pyrimidine low molecular weight ligands for modulating hormone receptors

Country Status (6)

Country Link
US (1) US20090203716A1 (enExample)
EP (1) EP2018384A2 (enExample)
JP (1) JP2009537551A (enExample)
AU (1) AU2007254165A1 (enExample)
CA (1) CA2652061A1 (enExample)
WO (1) WO2007136776A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5718233B2 (ja) 2008-10-20 2015-05-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
KR20110136819A (ko) 2009-02-27 2011-12-21 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방을 위한 티에노피리딘 유도체
WO2011127388A2 (en) 2010-04-08 2011-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inverse agonists and neutral antagonists for the tsh receptor
CA2893318A1 (en) * 2012-12-07 2014-06-12 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008528A1 (en) * 1989-01-11 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Biologically active synthetic thyrotropin and cloned gene for producing same
CA2339018A1 (en) * 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
TW564247B (en) * 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
US6426357B1 (en) * 1999-07-27 2002-07-30 Affymax, Inc. Antagonists of follicle stimulating hormone activity
CZ297136B6 (cs) * 2000-09-22 2006-09-13 Akzo Nobel N. V. Bicyklické heteroaromatické slouceniny
US20080004271A1 (en) * 2006-01-17 2008-01-03 Mckenna Jeffrey M Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith

Also Published As

Publication number Publication date
JP2009537551A (ja) 2009-10-29
EP2018384A2 (en) 2009-01-28
WO2007136776A3 (en) 2008-01-24
WO2007136776A2 (en) 2007-11-29
AU2007254165A1 (en) 2007-11-29
US20090203716A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
JP5918693B2 (ja) Ｅｇｆｒ阻害剤及び疾患の治療方法
US9126948B2 (en) Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
JP5498396B2 (ja) ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
JP2016169161A (ja) 新規イミダゾピリジン化合物
US9458141B2 (en) Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
JP6969800B2 (ja) 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US9902703B2 (en) Somatostatin modulators and uses thereof
US20180179210A1 (en) Inhibitors of the TEC Kinase Enzyme Family
CN102791705B (zh) 用于tsh受体的反向激动剂和中性拮抗剂
WO2024000401A1 (en) 2-((1-(6-methyl-4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives and similar compounds as pi3k inhibitors for the treatment of e.g. cancer
CA2652061A1 (en) Pyrimidine low molecular weight ligands for modulating hormone receptors
AU2005266493B2 (en) Inhibitors of Hsp90
KR20180085814A (ko) 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
CN106660968A (zh) 吡唑衍生物及其作为大麻素受体介体的用途
US20210122746A1 (en) Febrifugine derivatives
CN107827837B (zh) 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
US20160244485A1 (en) Nmda receptor modulators and prodrugs, salts, and uses thereof
CN105764906A (zh) 蛋白激酶抑制剂
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
CN117417324B (zh) 杂环甲酰胺类化合物及其药物组合物和应用
US20190119279A1 (en) Purine compounds and method for the treatment of cancer
WO2025139868A1 (zh) Trpv3抑制剂及其制备和应用
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
US20240034727A1 (en) Imidazole compounds as inhibitors of enpp1
WO2016050016A1 (zh) 作为激酶抑制剂的取代杂环化合物及其制备方法和用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130517